Study wrapper · #753
Mitochondrial-Derived Peptides: Implication in the Therapy of Neurodegenerative Diseases.
Editor's note
This systematic-style review evaluates mitochondrial-derived peptides, humanin, MOTS-c, and SHLPs, as candidates in Alzheimer's, Parkinson's, and Huntington's disease. MOTS-c features among the peptides discussed for antioxidant, neuroprotective, and anti-inflammatory mechanisms across disease models. The authors are candid that the field is limited by unclear molecular pathways, delivery challenges, and a lack of clinical translation, and much MOTS-c neuro work must contend with its reported poor blood-brain-barrier penetration. As a review it aggregates preclinical signals rather than testing outcomes, and makes no clinical claims. Publishable as orientation for readers tracking MOTS-c in neurodegeneration, with clear framing that this is an early, mechanism-level research area.
Plain-language abstract
This review looks at mitochondrial-derived peptides (MDPs), including MOTS-c, as possible treatments for brain-wasting diseases like Alzheimer's, Parkinson's, and Huntington's. It gathers studies suggesting these peptides can protect nerve cells, reduce oxidative stress, and calm inflammation in disease models. MOTS-c is discussed alongside humanin and a family called SHLPs. The authors are honest about big gaps: the exact ways these peptides work are still unclear, getting them into the brain is difficult (MOTS-c in particular is thought not to easily cross into the brain), and none have reached clinical use. Because this is a review of existing laboratory and animal research rather than a human trial, it does not show that MOTS-c helps people with these diseases. For readers, it provides a useful map of where the science stands and makes clear that MOTS-c's role in brain disease is an early, unproven research direction.